Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | CLL outcomes after CD19 CAR-T with ibrutinib

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discussed the clinical outcomes of patients with chronic lymphocytic leukemia (CLL) with relapsed or refractory disease after CD19-specific CAR-T therapy used concurrently with ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).